10 Best Performing Penny Stocks So Far in 2025

5. Atai Life Sciences N.V. (NASDAQ:ATAI)

Year-to-Date Performance: 142.50%

Share Price: $3.88

Number of Hedge Fund Holders: 14

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best-performing penny stocks so far in 2025. On July 2, Canaccord Genuity increased its price target for Atai Life Sciences N.V. (NASDAQ:ATAI) from $11 to $12 while keeping a “Buy” rating.

This decision came after Atai Life Sciences N.V. (NASDAQ:ATAI) and Beckley Psytech shared positive data from a Phase 2b clinical trial for BPL-003, an intranasal mebufotenin treatment for treatment-resistant depression (TRD). The study met its primary and all key secondary endpoints.

Atai Life Sciences N.V. (NASDAQ:ATAI) and Beckley Psytech plan to consult with the FDA to advance into Phase 3 clinical development for the 8mg dose of BPL-003. This positive data also supports Atai Life Sciences N.V.’s (NASDAQ:ATAI) previously announced plans to acquire Beckley, with the transaction expected to close in the second half of 2025.

Canaccord pointed out that if approved, BPL-003 could have a big commercial advantage as it might only require about two hours or less post-dose clinic time.

The research firm believes that Atai Life Sciences N.V. (NASDAQ:ATAI) is still “significantly undervalued relative to the sizes of the opportunities in the mental health indications it is targeting.”

Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that is focused on developing new mental health treatments to transform patient outcomes.